X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

SkyCell partners with All Nippon Airways to support Japanese pharma market

Content Team by Content Team
13th September 2021
in News, Packaging & Logistic
SkyCell partners with All Nippon Airways to support Japanese pharma market

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

At SkyCell, we have expanded our airline partnerships into Japan by partnering with All Nippon Airways (ANA), the country’s largest airline. This collaboration will not only strengthen our support for pharmaceutical customers shipping in and out of Japan, but will also benefit ANA in reaching their own sustainability goals.

Our partnership with ANA will include all the temperature ranges that we have, from -80°C to -60°C, -30°C to -15°C, +2°C to +8°C and +15°C to + 25°C. This gives their customers access to all cold chain internal temperature conditions to facilitate safe, secure and sustainable shipments. With Japan being a pivotal segment in the pharma market, our collaboration with ANA, as well as the utilization of our hybrid container solutions into their cold chain, will ensure the timely arrival of life-saving medicines in the region.

ANA and their customers will see why hybrid containers are an ideal solution to issues faced in modern pharma supply chains. Our hybrid containers can maintain stable temperatures without the need for external charging for long periods of time, meaning special infrastructure is not needed to keep the containers at optimal temperatures. By using lightweight, environmentally-friendly material, the technology enables efficiency and reusability. Additionally, they are shock-absorbent and can mitigate any breakage during transport, whilst a double-door system protects the packaging in high-humidity countries.

Furthermore, working towards a sustainable supply chain is also a fundamental part of our partnership. ANA, like many airlines, also has its own sustainability targets and seeks to collaborate with those who have a similar outlook. At SkyCell, sustainability is part of our DNA. We have joined the SBTi, launched our own sustainability report and committed to the Paris Agreement. By partnering with SkyCell, ANA has a collaborator that shares their sustainable vision, and will utilize containers that cut CO2 by half and don’t contribute to landfill waste.

Finally, SkyCell currently has one service center in Japan. This will also support the Japanese market with container availability and bring SkyCell’s hybrid to this essential segment of the pharma industry.

Previous Post

CEVEC and UCB sign agreement for the use of CEVECS ELEVECTA AAV manufacturing technology in Gene Therapy

Next Post

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In